Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

A non-NIH clinical trial is now testing ivermectin, the antiparasitic drug that became a lightning rod during the COVID-19 pandemic, as a potential weapon against one of the most aggressive forms of ...

Florida’s Republican Legislators want to make it easier to get ivermectin, the controversial anti-parasitic drug. Tucked into what has been called Florida’s Medical Freedom bill is a provision that ...

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

FDA grants first Emergency Use Authorization for an over-the-counter product for the prevention of New World screwworm infestations in cattle Ongoing detections in Mexico heighten the importance of ...